BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice

DSpace/Manakin Repository

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice

Citable link to this page

 

 
Title: BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice
Author: Hamouda, Mohamed-Amine; Jacquel, Arnaud; Robert, Guillaume; Puissant, Alexandre; Richez, Valentine; Cassel, Romeo; Fenouille, Nina; Roulland, Sandrine; Gilleron, Jerome; Griessinger, Emmanuel; Dubois, Alix; Bailly-Maitre, Beatrice; Goncalves, Diogo; Mallavialle, Aude; Colosetti, Pascal; Marchetti, Sandrine; Amiot, Martine; Gomez-Bougie, Patricia; Rochet, Nathalie; Deckert, Marcel; Avet-Loiseau, Herve; Hofman, Paul; Karsenti, Jean-Michel; Jeandel, Pierre-Yves; Blin-Wakkach, Claudine; Nadel, Bertrand; Cluzeau, Thomas; Anderson, Kenneth C.; Fuzibet, Jean-Gabriel; Auberger, Patrick; Luciano, Frederic

Note: Order does not necessarily reflect citation order of authors.

Citation: Hamouda, M., A. Jacquel, G. Robert, A. Puissant, V. Richez, R. Cassel, N. Fenouille, et al. 2016. “BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.” The Journal of Experimental Medicine 213 (9): 1705-1722. doi:10.1084/jem.20150983. http://dx.doi.org/10.1084/jem.20150983.
Full Text & Related Files:
Abstract: Multiple myeloma (MM) evolves from a premalignant condition known as monoclonal gammopathy of undetermined significance (MGUS). However, the factors underlying the malignant transformation of plasmocytes in MM are not fully characterized. We report here that Eµ-directed expression of the antiapoptotic Bcl-B protein in mice drives an MM phenotype that reproduces accurately the human disease. Indeed, with age, Eµ-bcl-b transgenic mice develop the characteristic features of human MM, including bone malignant plasma cell infiltration, a monoclonal immunoglobulin peak, immunoglobulin deposit in renal tubules, and highly characteristic bone lytic lesions. In addition, the tumors are serially transplantable in irradiated wild-type mice, underlying the tumoral origin of the disease. Eµ-bcl-b plasmocytes show increased expression of a panel of genes known to be dysregulated in human MM pathogenesis. Treatment of Eµ-bcl-b mice with drugs currently used to treat patients such as melphalan and VELCADE efficiently kills malignant plasmocytes in vivo. Finally, we find that Bcl-B is overexpressed in plasmocytes from MM patients but neither in MGUS patients nor in healthy individuals, suggesting that Bcl-B may drive MM. These findings suggest that Bcl-B could be an important factor in MM disease and pinpoint Eµ-bcl-b mice as a pertinent model to validate new therapies in MM.
Published Version: doi:10.1084/jem.20150983
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995074/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:31731780
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters